Talus Bio
YC S21Seattle, US · Founded 2020 · Delaware corporation · 16 employees · 7 known investors
Find your way into Talus Bio
585 people in our graph share verified history with the Talus Bio team — schools, employers, funds. One of them is your warm intro.
Talus develops a proprietary platform that measures and modulates the regulome—the body's gene expression control system—in native cellular contexts. The company designs AI-driven compounds and uses functional proteomics to enable drug discovery for transcription factors and regulatory proteins implicated in oncology, rare disease, and immune dysfunction.
Founders & leadership· Y Combinator alumni (S21)
Talus Bio was founded in 2020 by Alex Federation and Lindsay Pino.
Board
Investors · 7
Funding
SEC filings, press & company announcements$9.4M disclosed across 1 of 2 rounds · 2022–2024
- Undisclosed amountSeedJun 2022Source ↗
▶$9.4MraisedAug 2024 · 11 investors · Other TechnologyRule 506(b)
- Lindsay PinoExecutive Officer, Director
- Michelle BriscoeExecutive Officer
- Alex FederationExecutive Officer, Director, Promoter
- Omri Amirav-DroryDirector
- J. Seth StrattanDirector
- Offering amount
- $11.3M
- Amount sold
- $9.4M
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Talus Bio went on to found or lead other companies.
Competitors · 1
by search overlapCompanies competing with Talus Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 6 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2023 | $398.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2023 | $307.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2022 | $455K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $333.9K |
| National Science Foundation | Phase I | 2021 | $255.8K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Talus Bio do?
- Talus develops a proprietary platform that measures and modulates the regulome—the body's gene expression control system—in native cellular contexts. The company designs AI-driven compounds and uses functional proteomics to enable drug discovery for transcription factors and regulatory proteins implicated in oncology, rare disease, and immune dysfunction.
- Who founded Talus Bio?
- Talus Bio was founded by Alex Federation, Lindsay Pino in 2020.
- Who are Talus Bio's investors?
- Talus Bio's investors include Farvatn Venture, Fifty Years, FundersClub, NFX, Two Bear Capital, Y Combinator, BoxOne Ventures.
- How much funding has Talus Bio raised?
- Talus Bio has disclosed $9.4M raised across 1 of its 2 known rounds.
- Where is Talus Bio headquartered?
- Talus Bio is headquartered in Seattle, US.